Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHA In Brief

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific TAXUS I: Angiographic analysis at six-month follow-up of 61 patients demonstrated zero edge effect at the proximal and distal edges in both the treatment and control arm of the paclitaxel-coated Nirx stent trial. Intravascular ultrasound (IVUS) analysis showed "significant improvements" in neointimal volume, percent neointimal volume index and minimum lumen area in the treatment group, the firm says. The newly reported data "expand on the impressive results reported earlier, and they reduce the concern that an edge effect may be the price we pay for reducing in-stent restenosis," commented Eberhard Grube, MD, Seigburg Heart Center, Siegburg, Germany...

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts